ACE2, the Receptor that Enables Infection by SARS‐CoV‐2: Biochemistry, Structure, Allostery and Evaluation of the Potential Development of ACE2 Modulators
- 14 July 2020
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 15 (18) , 1682-1690
Abstract
Angiotensin converting enzyme 2 (ACE2) is the human receptor that interacts with the spike protein of coronaviruses, including the one that produced the 2020 coronavirus pandemic (COVID‐19). Thus, ACE2 is a potential target for drugs that disrupt the interaction of human cells with SARS‐CoV‐2 to abolish infection. There is also interest in drugs that inhibit or activate ACE2, that is, for cardiovascular disorders or colitis. Compounds binding at alternative sites could allosterically affect the interaction with the spike protein. Herein, we review biochemical, chemical biology, and structural information on ACE2, including the recent cryoEM structures of full‐length ACE2. We conclude that ACE2 is very dynamic and that allosteric drugs could be developed to target ACE2. At the time of the 2020 pandemic, we suggest that available ACE2 inhibitors or activators in advanced development should be tested for their ability to allosterically displace the interaction between ACE2 and the spike protein.Keywords
Funding Information
- Consejo Nacional de Investigaciones Científicas y Técnicas
- Agencia Nacional de Promoción Científica y Tecnológica (PICT PRH-2016-4835, PICT 2016–3525, PICT 2017–0388)
This publication has 64 references indexed in Scilit:
- The Underappreciated Role of Allostery in the Cellular NetworkAnnual Review of Biophysics, 2013
- Evidence that TMPRSS2 Activates the Severe Acute Respiratory Syndrome Coronavirus Spike Protein for Membrane Fusion and Reduces Viral Control by the Humoral Immune ResponseJournal of Virology, 2011
- A Transmembrane Serine Protease Is Linked to the Severe Acute Respiratory Syndrome Coronavirus Receptor and Activates Virus EntryJournal of Virology, 2011
- Ectodomain shedding of angiotensin converting enzyme 2 in human airway epitheliaAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2009
- Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive AgentsHypertension, 2008
- Development of Potent and Selective Phosphinic Peptide Inhibitors of Angiotensin-Converting Enzyme 2Journal of Medicinal Chemistry, 2008
- Calmodulin interacts with angiotensin‐converting enzyme‐2 (ACE2) and inhibits shedding of its ectodomainFEBS Letters, 2007
- Conformational Reorganization of the SARS Coronavirus Spike Following Receptor Binding: Implications for Membrane FusionPLOS ONE, 2007
- Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 InhibitorHypertension, 2004
- The Coronavirus Spike Protein Is a Class I Virus Fusion Protein: Structural and Functional Characterization of the Fusion Core ComplexJournal of Virology, 2003